Alembic Pharmaceuticals has nabbed FDA approval of its generic doxycycline hyclate delayed-release tablets — an antibiotic medication used to treat a range of infections that is also meant to help reduce the emergence of drug-resistant bacteria.

The delayed-release doxycycline hyclate tablets will be available in 75 mg, 100 mg, 150 mg and 200 mg dosages.

The tablets were deemed therapeutically equivalent to their reference listed drug product, Mayne Pharma International’s Doryx brand pills.

Alembic is based in Vadodara, India.